40 related articles for article (PubMed ID: 26946092)
1. Equivalency challenge: Evaluation of Lipodox® as the generic equivalent for Doxil® in a human ovarian cancer orthotropic mouse model.
Smith JA; Mathew L; Burney M; Nyshadham P; Coleman RL
Gynecol Oncol; 2016 May; 141(2):357-363. PubMed ID: 26946092
[TBL] [Abstract][Full Text] [Related]
2. Anti-CD30 antibody conjugated liposomal doxorubicin with significantly improved therapeutic efficacy against anaplastic large cell lymphoma.
Molavi O; Xiong XB; Douglas D; Kneteman N; Nagata S; Pastan I; Chu Q; Lavasanifar A; Lai R
Biomaterials; 2013 Nov; 34(34):8718-8725. PubMed ID: 23942212
[TBL] [Abstract][Full Text] [Related]
3. Tumor suppression effect of ultrasound-sensitive nanoparticles with focused ultrasound in a pancreas cancer xenograft model.
Kim S; Lee JY; Park EJ; Ahn YD; Cheon Y; Sim W; Lee HJ
Eur Radiol Exp; 2024 Mar; 8(1):39. PubMed ID: 38503996
[TBL] [Abstract][Full Text] [Related]
4. TXB-001, a newly-developed polymer-conjugated anthracycline: Significantly lower adverse effects in animal models of alopecia and hand-foot syndrome.
Hirakata M; Tomikawa E; Sakai C; Uchida M; Okano T; Shimozono R; Kawai M; Itaba S; Munakata L; Suzuki R; Oshida K
Toxicol Appl Pharmacol; 2024 Apr; 485():116912. PubMed ID: 38521368
[TBL] [Abstract][Full Text] [Related]
5. Understanding the In Vitro-In Vivo Nexus: Advanced correlation models predict clinical performance of liposomal doxorubicin.
Gan K; Li Z; Darli PM; Wong T; Modh H; Gottier P; Halbherr S; Wacker MG
Int J Pharm; 2024 Apr; 654():123942. PubMed ID: 38403086
[TBL] [Abstract][Full Text] [Related]
6. A Design-Conversed Strategy Establishes the Performance Safe Space for Doxorubicin Nanosimilars.
Nagpal S; Png Yi Jie J; Malinovskaya J; Kovshova T; Jain P; Naik S; Khopade A; Bhowmick S; Shahi P; Chakra A; Bhokari A; Shah V; Gelperina S; Wacker MG
ACS Nano; 2024 Feb; 18(8):6162-6175. PubMed ID: 38359902
[TBL] [Abstract][Full Text] [Related]
7. Liposomal Doxorubicin In vitro and In vivo Assays in Non-small Cell Lung Cancer: A Systematic Review.
Redruello-Guerrero P; Cordoba P; Láinez-Ramos-Bossini A; Rivera M; Mesas C; Ortiz R; Prados J; Perazzoli G
Curr Drug Deliv; 2023 Nov; ():. PubMed ID: 38099532
[TBL] [Abstract][Full Text] [Related]
8. Liposomal doxorubicin: the good, the bad and the not-so-ugly.
Szebeni J; Fülöp T; Dézsi L; Metselaar B; Storm G
J Drug Target; 2016 Nov; 24(9):765-767. PubMed ID: 27030293
[TBL] [Abstract][Full Text] [Related]
9. Regulatory assessment of nano-enabled health products in public health interest. Position of the scientific advisory board of the French National Agency for the Safety of Medicines and Health Products.
Oualikene-Gonin W; Sautou V; Ezan E; Bastos H; Bellissant E; Belgodère L; Maison P; Ankri J;
Front Public Health; 2023; 11():1125577. PubMed ID: 36935690
[TBL] [Abstract][Full Text] [Related]
10. Doxorubicin-An Agent with Multiple Mechanisms of Anticancer Activity.
Kciuk M; Gielecińska A; Mujwar S; Kołat D; Kałuzińska-Kołat Ż; Celik I; Kontek R
Cells; 2023 Feb; 12(4):. PubMed ID: 36831326
[TBL] [Abstract][Full Text] [Related]
11. Anticancer Nanotherapeutics in Clinical Trials: The Work behind Clinical Translation of Nanomedicine.
Parodi A; Kolesova EP; Voronina MV; Frolova AS; Kostyushev D; Trushina DB; Akasov R; Pallaeva T; Zamyatnin AA
Int J Mol Sci; 2022 Nov; 23(21):. PubMed ID: 36362156
[TBL] [Abstract][Full Text] [Related]
12. Beyond Formulation: Contributions of Nanotechnology for Translation of Anticancer Natural Products into New Drugs.
Miguel RDA; Hirata AS; Jimenez PC; Lopes LB; Costa-Lotufo LV
Pharmaceutics; 2022 Aug; 14(8):. PubMed ID: 36015347
[TBL] [Abstract][Full Text] [Related]
13. Recent Advances in Nanoparticle-Based Co-Delivery Systems for Cancer Therapy.
Al Bostami RD; Abuwatfa WH; Husseini GA
Nanomaterials (Basel); 2022 Aug; 12(15):. PubMed ID: 35957103
[TBL] [Abstract][Full Text] [Related]
14. Development of Pharmaceutical Nanomedicines: From the Bench to the Market.
Halwani AA
Pharmaceutics; 2022 Jan; 14(1):. PubMed ID: 35057002
[TBL] [Abstract][Full Text] [Related]
15. The Growing Field of Nanomedicine and Its Relevance to Pharmacy Curricula.
Weissig V; Elbayoumi T; Flühmann B; Barton A
Am J Pharm Educ; 2021 Sep; 85(8):8331. PubMed ID: 34615620
[TBL] [Abstract][Full Text] [Related]
16. Iron-crosslinked Rososome with robust stability and high drug loading for synergistic cancer therapy.
Xue X; Ricci M; Qu H; Lindstrom A; Zhang D; Wu H; Lin TY; Li Y
J Control Release; 2021 Jan; 329():794-804. PubMed ID: 33039481
[TBL] [Abstract][Full Text] [Related]
17. Drug Exposure to Establish Pharmacokinetic-Response Relationships in Oncology.
Solans BP; Garrido MJ; Trocóniz IF
Clin Pharmacokinet; 2020 Feb; 59(2):123-135. PubMed ID: 31654368
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics and Pharmacodynamics Modeling and Simulation Systems to Support the Development and Regulation of Liposomal Drugs.
He H; Yuan D; Wu Y; Cao Y
Pharmaceutics; 2019 Mar; 11(3):. PubMed ID: 30866479
[TBL] [Abstract][Full Text] [Related]
19. Stimulus-responsive liposomes as smart nanoplatforms for drug delivery applications.
Zangabad PS; Mirkiani S; Shahsavari S; Masoudi B; Masroor M; Hamed H; Jafari Z; Taghipour YD; Hashemi H; Karimi M; Hamblin MR
Nanotechnol Rev; 2018 Feb; 7(1):95-122. PubMed ID: 29404233
[TBL] [Abstract][Full Text] [Related]
20. Personalized Nanomedicine: A Revolution at the Nanoscale.
Fornaguera C; García-Celma MJ
J Pers Med; 2017 Oct; 7(4):. PubMed ID: 29023366
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
